A large study found many diabetic individuals who self-administer insulin are incorrectly injecting the treatment, prompting experts to create formal recommendations, Reuters reported. Of the 13,289 ...

An international expert panel has recently released a comprehensive set of recommendations for optimal insulin injection techniques and equipment. The group, called the Forum for Injection Technique ...

(1,2) "Awiqli (R) is an important new option that meets a real need as the first FDA-approved, once-weekly basal insulin for adult patients with type 2 diabetes. It's helping to reframe what basal ...

Insulin icodec, a once-weekly basal injection to treat type 1 diabetes, has the potential to be as effective in managing the condition as daily basal insulin treatments, according to research from the ...

CNW/ -- (SSE: 603087) today announced that two pivotal phase 3 clinical trials, SUPER-1 and SUPER-2, evaluating ...

The US Food and Drug Administration has approved insulin icodec (Awiqli), developed by Novo Nordisk, as the first once-weekly long-acting basal insulin for glycemic control in adults with Type ...

If youre on insulin to treat type 1 or type 2 diabetes, its critical to know exactly how to use it. Insulin can be a very dangerous drug if used improperly, says Stanley Mathew, MD, an endocrinologist ...

Incorporating insulin into your daily life can take some getting used to. From packing your on-the-go bag to prepping your syringe or insulin pen, here are tips to get you started. Insulin may be one ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin ...